Does “late catch-up” exist in drug-eluting stents: Insights from a serial quantitative coronary angiography analysis of sirolimus versus paclitaxel-eluting stents

Five-Year Clinical and Angiographic Outcomes of a Randomized Comparison of Sirolimus-Eluting and Paclitaxel-Eluting Stents

“…Previous serial angiographic studies of nonrandomized cohorts support the notion that luminal LL continues to accrue with firstgeneration DES and that delayed LL of SES numerically exceeds that observed with PES. 17 However, the risk of TLR in the present study of patients with percutaneous coronary intervention of multiple lesions amounted to only 1.7% per year, which is well in agreement with previous studies comparing DES with BMS in lower-risk patient populations. The risk of TLR was even lower (1.2% per year) when revascularization events related to the treatment of ST were subtracted.…”

Clinical Outcomes of Drug-Eluting Stents vs. Bare-Metal Stents in Acute Myocardial Infarction Patients Under Dialysis – A Nationwide Cohort Study –

“…25-29 Hemodialysis has also been reported to be an independent predictor of late catch-up phenomenon, 30 and it occurs with both paclitaxel-and sirolimus-eluting stents. 31 Consistent with those studies, our results confirmed late catch-up phenomenon in the AMI patients under dialysis who received DES compared with those who received BMS.…”

CABG Versus PCI in the Treatment of Diabetic Patients Affected by Coronary Artery Disease

“…Although a previous study showed a sustained clinical benefit after sirolimus eluting-stents (SES) implantation, 25) little is known about long-term angiographic outcomes, and concerns have been raised about the late restenosis of SES. 26) Recent studies have suggested the possibility of "late catch-up" phenomenon after SES implantation, 27,28) which was significantly more pronounced with SES than that with BMS in the recent study of Natsuaki, et al 29) "Late catch-up" phenomenon is strictly related to late adverse events such as late stent thrombosis and late target-lesion revascularization and then may be an important explanation of the worse results of these DES first-generation with respect to CABG. Whether CABG will confirm superiority over PCI with newer-generation DES in diabetic patients remains a matter of debate.…”